SCHEMBL23965748

SCHEMBL23965748

COCCN1CCN(c2nc3ccccc3s2)CC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.69
NPC1 O15118 5/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
CYP1A2 P05177 1/20 0.69
POLB P06746 1/20 0.69
CYP2D6 P10635 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP2C19 P33261 1/20 0.69
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
PKM P14618 1/20 0.61
DRD4 P21917 1/20 0.60
GRM2 Q14416 1/20 0.60
MAPT P10636 2/20 0.59
LMNA P02545 3/20 0.59
ALDH1A1 P00352 2/20 0.58
TSHR P16473 2/20 0.58
PPARG P37231 1/20 0.58
NCOA2 Q15596 1/20 0.58
NCOA1 Q15788 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21638143 0.83 RAB9A (0.58) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL7780288 0.82 RAB9A (0.70) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL3157852 0.82 RAB9A (1.00) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL28142588 0.81 RAB9A (0.72) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL15941384 0.80 RAB9A (0.67) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL7534676 0.80 RAB9A (0.67) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL6125228 0.80 RAB9A (0.70) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL27652569 0.78 RAB9A (0.72) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL7760900 0.77 RAB9A (1.00) RAB9ANPC1SMN1; SMN2CYP1A2POLB
SCHEMBL9382129 0.77 DRD2 (0.58) RAB9ANPC1SMN1; SMN2CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161830-B2 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same FUJIFILM CORPORATION (JP) 2021-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161830-B2 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same HAVCR2, HBS1L, PHKB RAB9A 2878/4885NPC1 1739/4885SMN1; SMN2 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.